Nothing Special   »   [go: up one dir, main page]

DK1259485T3 - Benzamider og beslægtede inhibitorer for faktor Xa - Google Patents

Benzamider og beslægtede inhibitorer for faktor Xa

Info

Publication number
DK1259485T3
DK1259485T3 DK01918257T DK01918257T DK1259485T3 DK 1259485 T3 DK1259485 T3 DK 1259485T3 DK 01918257 T DK01918257 T DK 01918257T DK 01918257 T DK01918257 T DK 01918257T DK 1259485 T3 DK1259485 T3 DK 1259485T3
Authority
DK
Denmark
Prior art keywords
factor
benzamides
compounds
related inhibitors
compositions
Prior art date
Application number
DK01918257T
Other languages
English (en)
Inventor
Penglie Zhang
Lingyan Wang
Wenrong Huang
Wenhao Li
Yonghong Song
Robert Scarborough
Bing-Yan Zhu
Erick Goldman
Jingmei Zuckett
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26881428&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1259485(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US09/663,420 external-priority patent/US6844367B1/en
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Application granted granted Critical
Publication of DK1259485T3 publication Critical patent/DK1259485T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/12—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines
    • C07C259/18—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines having carbon atoms of hydroxamidine groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
    • C07C317/40—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
DK01918257T 2000-02-29 2001-02-28 Benzamider og beslægtede inhibitorer for faktor Xa DK1259485T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18574600P 2000-02-29 2000-02-29
US09/663,420 US6844367B1 (en) 1999-09-17 2000-09-15 Benzamides and related inhibitors of factor Xa

Publications (1)

Publication Number Publication Date
DK1259485T3 true DK1259485T3 (da) 2006-04-10

Family

ID=26881428

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01918257T DK1259485T3 (da) 2000-02-29 2001-02-28 Benzamider og beslægtede inhibitorer for faktor Xa

Country Status (10)

Country Link
US (13) US6376515B2 (da)
EP (1) EP1259485B1 (da)
AT (1) ATE311366T1 (da)
AU (2) AU2001250783A1 (da)
CA (1) CA2401778C (da)
DE (1) DE60115394T2 (da)
DK (1) DK1259485T3 (da)
ES (1) ES2254385T3 (da)
HK (1) HK1051539A1 (da)
WO (2) WO2001064643A2 (da)

Families Citing this family (224)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6822267B1 (en) * 1997-08-20 2004-11-23 Advantest Corporation Signal transmission circuit, CMOS semiconductor device, and circuit board
AU2001250783A1 (en) 2000-02-29 2001-09-12 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
AU776053B2 (en) 2000-03-31 2004-08-26 Astellas Pharma Inc. Diazepan derivatives or salts thereof
TWI288745B (en) 2000-04-05 2007-10-21 Daiichi Seiyaku Co Ethylenediamine derivatives
US7160878B2 (en) 2000-07-27 2007-01-09 Eli Lilly And Company Substituted heterocyclic amides
MXPA03003572A (es) 2000-11-22 2003-07-14 Yamanouchi Pharma Co Ltd Derivados de benceno sustituidos o sales de los mismos.
US7163938B2 (en) * 2000-11-28 2007-01-16 Eli Lilly And Company Substituted carboxamides
US7067539B2 (en) 2001-02-08 2006-06-27 Schering Corporation Cannabinoid receptor ligands
US7507767B2 (en) 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
US7312235B2 (en) * 2001-03-30 2007-12-25 Millennium Pharmaceuticals, Inc. Benzamide inhibitors of factor Xa
WO2003000657A1 (fr) 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Derives de diamine
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
AUPR738301A0 (en) * 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
WO2003024448A2 (en) 2001-09-14 2003-03-27 Methylgene, Inc. Inhibitors of histone deacetylase
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
CA2466440A1 (en) 2001-11-14 2003-05-22 Schering Corporation Cannabinoid receptor ligands
EP1314733A1 (en) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
US7449457B2 (en) 2001-12-07 2008-11-11 Eli Lilly And Company Substituted heterocyclic carboxamides with antithrombotic activity
EP1569912B1 (en) 2002-12-03 2015-04-29 Pharmacyclics, Inc. 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
AU2003223708A1 (en) * 2002-04-23 2003-11-10 Axys Pharmaceuticals, Inc. Novel phenyl derivatives as inducers of apoptosis
AU2003243637A1 (en) 2002-06-19 2004-01-06 Schering Corporation Cannabinoid receptor agonists
TW200409637A (en) 2002-06-26 2004-06-16 Glaxo Group Ltd Compounds
GB0215293D0 (en) * 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
US7307088B2 (en) * 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
AU2003283265B2 (en) 2002-10-18 2009-03-05 F. Hoffmann-La Roche Ag 4-piperazinyl benzenesulfonyl indoles with 5-HT6 receptor affinity
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
US7696225B2 (en) 2003-01-06 2010-04-13 Osi Pharmaceuticals, Inc. (2-carboxamido)(3-Amino) thiophene compounds
TWI299664B (en) 2003-01-06 2008-08-11 Osi Pharm Inc (2-carboxamido)(3-amino)thiophene compounds
TW200505447A (en) 2003-02-07 2005-02-16 Daiichi Seiyaku Co Pyrazole derivative
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
NZ543366A (en) 2003-04-03 2008-11-28 Merck Patent Gmbh Carbonyl compounds
DE502004003688D1 (de) * 2003-04-03 2007-06-14 Merck Patent Gmbh Pyrazolidin-1,2-dicarbonsäure-1-((phenyl)-amid)-2-((phenyl)-amid) derivate als koagulationsfaktor xa inhibitoren zur behandlung von thrombosen
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
EP2256106B1 (en) 2003-07-22 2015-05-06 Astex Therapeutics Limited 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
EP1667992B1 (en) 2003-09-19 2007-01-24 Astrazeneca AB Quinazoline derivatives
CA2539117A1 (en) 2003-09-24 2005-04-07 Methylgene Inc. Inhibitors of histone deacetylase
SE0302573D0 (sv) * 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
EP1670783A2 (en) * 2003-09-30 2006-06-21 Eli Lilly And Company Antithrombotic aromatic ethers
JP4667384B2 (ja) 2003-10-07 2011-04-13 レノビス， インコーポレイテッド イオンチャネルリガンドとしてのアミド誘導体および薬学的組成物、ならびにこれらを使用する方法
ES2338881T3 (es) * 2003-10-09 2010-05-13 Millennium Pharmaceuticals, Inc. Benzamidas sustituidas con tioeter como inhibidores del factor xa.
SI2161273T1 (sl) * 2003-12-22 2015-10-30 K.U.Leuven Research & Development Imidazo(4,5-c)piridin spojine in postopki protivirusnega zdravljenja
PL1706385T3 (pl) 2003-12-23 2011-03-31 Astex Therapeutics Ltd Pochodne pirazolu jako modulatory kinazy białkowej
WO2005073193A1 (en) * 2004-01-23 2005-08-11 Amgen Inc. Vanilloid receptor ligands and their use in treatments
AU2005214137B2 (en) * 2004-02-18 2008-05-29 Astrazeneca Ab Compounds
ATE426597T1 (de) * 2004-02-18 2009-04-15 Astrazeneca Ab Benzamidderivate und deren verwendung als glucokinaseaktivierende mittel
US7253204B2 (en) * 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
US7166738B2 (en) 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
US7625949B2 (en) 2004-04-23 2009-12-01 Roche Palo Alto Llc Methods for treating retroviral infections
TW200600086A (en) * 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
AU2005257999B2 (en) 2004-06-18 2011-12-08 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
US7696352B2 (en) * 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
MX2007000791A (es) 2004-08-03 2007-03-23 Wyeth Corp Indazoles utiles en el tratamiento de enfermedades cardiovasculares.
KR101269869B1 (ko) * 2004-09-24 2013-06-07 네오메드 인스티튜트 벤즈이미다졸 유도체, 그를 함유하는 조성물, 그의 제조방법 및 그의 용도
GB0422556D0 (en) * 2004-10-11 2004-11-10 Syngenta Participations Ag Novel insecticides
GB0423043D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
GB0423044D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
WO2006040527A1 (en) 2004-10-16 2006-04-20 Astrazeneca Ab Process for making phenoxy benzamide compounds
JP2008517930A (ja) 2004-10-21 2008-05-29 トランス テック ファーマ，インコーポレイテッド ＧａｌＲ１のアゴニストとしてのビススルホンアミド化合物、組成物、及び使用法
ATE496030T1 (de) 2004-11-03 2011-02-15 Hoffmann La Roche Dicarbonsäureamidderivate und deren verwendung als inhibitoren von faktor xa
ES2339138T3 (es) 2004-11-24 2010-05-17 Eli Lilly And Company Derivados de eteres aromaticos utiles como inhibidores de la trombina.
WO2006057868A1 (en) * 2004-11-29 2006-06-01 Eli Lilly And Company Antithrombotic diamides
EP1824831A2 (en) 2004-12-16 2007-08-29 Takeda San Diego, Inc. Histone deacetylase inhibitors
AU2005319167B2 (en) * 2004-12-21 2011-09-29 Gilead Sciences, Inc. Imidazo[4,5-C]pyridine compound and method of antiviral treatment
EP1833819A1 (en) 2004-12-30 2007-09-19 Astex Therapeutics Limited Pyrazole compounds that modulate the activity of cdk, gsk and aurora kinases
WO2006083477A2 (en) 2005-01-07 2006-08-10 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
BRPI0606480A (pt) 2005-01-21 2008-03-11 Astex Therapeutics Ltd compostos farmacêuticos
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
MX2007008781A (es) 2005-01-21 2007-09-11 Astex Therapeutics Ltd Compuestos farmaceuticos.
WO2006083003A1 (ja) * 2005-02-02 2006-08-10 Ajinomoto Co., Inc. 新規ベンズアミジン化合物
US7576099B2 (en) 2005-02-28 2009-08-18 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
US7264402B2 (en) * 2005-03-10 2007-09-04 Corning Cable Systems Llc Multi-fiber optic receptacle and plug assembly
ATE443056T1 (de) 2005-03-10 2009-10-15 Pfizer Substituierte n-sulfonylaminophenylethyl-2- phenoxyacetamidverbindungen
WO2006122319A2 (en) 2005-05-11 2006-11-16 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20110059941A1 (en) * 2005-05-24 2011-03-10 Peter William Rodney Caulkett 2-phenyl substituted imidazol [4,5b] pyridine/pyrazine and purine derivatives as glucokinase modulators
TW200714597A (en) * 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
EP1902032A1 (en) 2005-06-22 2008-03-26 Astex Therapeutics Limited Pharmaceutical compounds
EP1933832A2 (en) 2005-06-23 2008-06-25 Astex Therapeutics Limited Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
WO2007007041A1 (en) * 2005-07-09 2007-01-18 Astrazeneca Ab Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
US20080234273A1 (en) * 2005-07-09 2008-09-25 Mckerrecher Darren Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes
US20110053910A1 (en) * 2005-07-09 2011-03-03 Mckerrecher Darren 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
ZA200800901B (en) * 2005-07-14 2010-05-26 Takeda San Diego Inc Histone deacetylase inhibitors
US9202182B2 (en) * 2005-08-11 2015-12-01 International Business Machines Corporation Method and system for analyzing business architecture
DK1940786T3 (da) 2005-09-16 2010-11-08 Arrow Therapeutics Ltd Biphenylderivater og deres anvendelse ved behandling af hepatitis C
BRPI0617720A2 (pt) 2005-10-19 2011-08-02 Hoffmann La Roche compostos inibidores de nnrt de fenil-acetamida, usos dos referidos compostos e composição farmacêutica que os contém
JP5227178B2 (ja) * 2005-11-08 2013-07-03 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｎ−（５−クロロ−２−ピリジニル）−２−［［４−［（ジメチルアミノ）イミノメチル］ベンゾイル］アミノ］−５−メトキシ−ベンズアミド、第Ｘａ因子阻害剤の薬学的な塩および多形体
TW200738621A (en) * 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
US8399442B2 (en) 2005-12-30 2013-03-19 Astex Therapeutics Limited Pharmaceutical compounds
WO2007084390A2 (en) * 2006-01-13 2007-07-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1991226B1 (en) 2006-02-28 2013-03-20 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase
TW200745049A (en) * 2006-03-23 2007-12-16 Astrazeneca Ab New crystalline forms
WO2007112367A2 (en) * 2006-03-27 2007-10-04 Portola Pharmaceuticals, Inc. Potassium channel modulators and platelet procoagulant activity
JP2009531385A (ja) 2006-03-31 2009-09-03 グラクソ グループ リミテッド 成長ホルモン分泌促進物質（ｇｈｓ）受容体アゴニストとしてのピペラジン誘導体
CN101466670B (zh) 2006-04-07 2013-04-17 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
TW200808769A (en) * 2006-04-18 2008-02-16 Astrazeneca Ab Therapeutic compounds
EP2016072B1 (en) 2006-05-05 2014-07-16 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
WO2008001101A2 (en) * 2006-06-29 2008-01-03 Astex Therapeutics Limited Pharmaceutical combinations
WO2008001115A2 (en) 2006-06-29 2008-01-03 Astex Therapeutics Limited Pharmaceutical combinations of 1-cyclopropyl-3- [3- (5-m0rphoolin-4-ylmethyl-1h-benzoimidazol-2-yl) -lh-1-pyrazol- 4-yl] -urea
EA019452B1 (ru) * 2006-07-07 2014-03-31 Джилид Сайэнс, Инк. 5-({6-[2,4-БИС-(ТРИФТОРМЕТИЛ)ФЕНИЛ]ПИРИДАЗИН-3-ИЛ}МЕТИЛ)-2-(2-ФТОРФЕНИЛ)-5Н-ИМИДАЗО[4,5-c]ПИРИДИН, СПОСОБ ЕГО ПОЛУЧЕНИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ИНФЕКЦИОННОГО ВИРУСНОГО ГЕПАТИТА С С ЕГО ПОМОЩЬЮ, КОМПОЗИЦИЯ И ЛЕКАРСТВЕННОЕ СРЕДСТВО НА ЕГО ОСНОВЕ
TW200825063A (en) * 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
TW200825060A (en) * 2006-10-26 2008-06-16 Astrazeneca Ab Chemical compounds
AU2007317376B2 (en) 2006-11-02 2013-01-17 Millennium Pharmaceuticals, Inc. Methods of synthesizing pharmaceutical salts of a Factor Xa inhibitor
AU2007320906A1 (en) * 2006-11-13 2008-05-22 Pfizer Products Inc. Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
SG10201504425SA (en) * 2006-12-08 2015-07-30 Millennium Pharm Inc Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor
US20100094009A1 (en) * 2006-12-21 2010-04-15 Mccabe James Novel crystalline compound useful as glk activator
CA2674924A1 (en) * 2007-01-05 2008-07-17 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
UY30892A1 (es) * 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
WO2008112938A2 (en) 2007-03-13 2008-09-18 New England Medical Center Hospitals, Inc. Composition and method for the treatment of diseases affected by a peptide receptor
GB0704932D0 (en) 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds
EP2155195B1 (en) 2007-04-13 2014-07-16 Millennium Pharmaceuticals, Inc. Combination anticoagulant therapy with a compound that acts as a factor Xa inhibitor
US20080279845A1 (en) * 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. Combination therapy with a compound acting as a platelet adp receptor inhibitor
UA99466C2 (en) 2007-07-06 2012-08-27 Гилиад Сайенсиз, Инк. Crystalline pyridazine compound
PT2193196T (pt) 2007-09-28 2016-10-24 Portola Pharm Inc Antídotos para inibidores do fator xa e métodos de utilização dos mesmos
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
BRPI0917589A2 (pt) 2008-08-04 2015-11-17 Astrazeneca Ab composto, composição farmacêutica, uso de um composto, método para tratar doenças, processo, combinação farmacêutica, e, reação de metiloxirano-2-carboxilato (ix) com um álcool roh
CA2743496C (en) 2008-11-14 2018-03-27 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
PE20120003A1 (es) * 2009-01-30 2012-02-12 Glaxosmithkline Llc Hidrocloruro de n-{(1s)-2-amino-1-[(3-fluorofenil)metil)etil}-5-cloro-4-(4-cloro-1-metil-1h-pirazol-5-il)-2-tiofenocarboxamida cristalino
GB0902406D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
GB0902434D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
CA2755394C (en) 2009-03-13 2021-10-19 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
EP2414517B1 (en) 2009-03-30 2016-09-21 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
AU2010234526B2 (en) 2009-04-06 2016-07-21 Agios Pharmaceuticals, Inc. Pyruvate kinase M2 modulators, therapeutic compositions and related methods of use
WO2010116177A1 (en) 2009-04-09 2010-10-14 Astrazeneca Ab A pyrazolo [4,5-e] pyrimidine derivative and its use to treat diabetes and obesity
WO2010116176A1 (en) * 2009-04-09 2010-10-14 Astrazeneca Ab Pyrazolo [4, 5-e] pyrimidine derivative and its use to treat diabetes and obesity
TWI691493B (zh) 2009-06-29 2020-04-21 美商阿吉歐斯製藥公司 治療化合物及組成物
US9056106B2 (en) 2009-07-15 2015-06-16 Portola Pharmaceuticals, Inc. Unit dose formulation of antidotes for factor Xa inhibitors and methods of using the same
US20110086853A1 (en) * 2009-10-08 2011-04-14 William Brown Therapeutic Compounds
CA2793835C (en) 2009-10-21 2021-07-20 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
WO2011075602A1 (en) * 2009-12-17 2011-06-23 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
WO2011084652A2 (en) 2009-12-17 2011-07-14 Millennium Pharmaceuticals, Inc. Salts and crystalline forms of a factor xa inhibitor
TW201144283A (en) 2009-12-17 2011-12-16 Millennium Pharm Inc Methods of synthesizing factor Xa inhibitors
EA015918B1 (ru) * 2010-03-03 2011-12-30 Дмитрий Геннадьевич ТОВБИН УРЕТАНЫ, МОЧЕВИНЫ, АМИДЫ И РОДСТВЕННЫЕ ИНГИБИТОРЫ ФАКТОРА Xa
EP2575453B1 (en) 2010-05-28 2018-08-01 The Board of Regents of the University of Texas System Oligo-benzamide compounds and their use
EP2590656B1 (en) 2010-07-07 2017-11-15 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
EP2590510B1 (en) 2010-07-07 2016-09-28 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
JP5827326B2 (ja) 2010-07-07 2015-12-02 アーデリクス，インコーポレーテッド リン酸輸送を阻害する化合物及び方法
EP2590965B1 (en) 2010-07-07 2016-04-20 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
TW201221128A (en) 2010-09-01 2012-06-01 Portola Pharm Inc Crystalline forms of a factor Xa inhibitor
TW201240664A (en) 2010-09-01 2012-10-16 Portola Pharm Inc Methods and formulations of treating thrombosis with betrixaban and a P-glycoprotein inhibitor
CA2821975A1 (en) 2010-12-17 2012-06-21 Shunqi Yan N-(4-(azetidine-1-carbonyl)phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase m2 pkm2 modulators
US9328077B2 (en) 2010-12-21 2016-05-03 Agios Pharmaceuticals, Inc Bicyclic PKM2 activators
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
CA2824885A1 (en) 2011-01-19 2012-07-26 Bayer Intellectual Property Gmbh Binding proteins to inhibitors of coagulation factors
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
SG10201609196QA (en) 2011-05-03 2016-12-29 Agios Pharmaceuticals Inc Pyruvate kinase activators for use in therapy
CN103608016A (zh) 2011-05-03 2014-02-26 安吉奥斯医药品有限公司 丙酮酸激酶激活剂在治疗中的用途
CN103619170B (zh) 2011-05-04 2016-07-06 默沙东公司 含有氨基-吡啶的脾酪氨酸激酶(syk)抑制剂
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
WO2013033370A1 (en) 2011-08-31 2013-03-07 Portola Pharmaceuticals, Inc. Prevention and treatment of thrombosis in medically ill patients
CA2846222C (en) 2011-10-03 2020-07-07 Respivert Limited 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1- yl) ureas as p38 map kinase inhibitors
EP2578582A1 (en) 2011-10-03 2013-04-10 Respivert Limited 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
US8835493B2 (en) 2011-11-23 2014-09-16 Board Of Regents, The University Of Texas System Oligo-benzamide compounds for use in treating cancers
WO2013078277A1 (en) 2011-11-23 2013-05-30 The Board Of Regents Of The University Of Texas System Oligo-benzamide compounds and their use in treating cancers
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
BR112014026703B1 (pt) 2012-04-24 2022-10-25 Vertex Pharmaceuticals Incorporated Inibidores de dna-pk e seus usos, composição farmacêutica e seus usos, e método de sensibilização de uma célula
GB201214750D0 (en) 2012-08-17 2012-10-03 Respivert Ltd Compounds
GB201215357D0 (en) 2012-08-29 2012-10-10 Respivert Ltd Compounds
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
JP2015531395A (ja) 2012-10-04 2015-11-02 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ ピロロ［３，２−ｃ］ピリジントロポミオシン関連キナーゼ阻害剤
US9200268B2 (en) 2012-12-27 2015-12-01 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
US20140346397A1 (en) 2012-12-27 2014-11-27 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
FR3000895B1 (fr) 2013-01-11 2017-02-24 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Sa Utilisation d'antidotes d'inhibiteurs de la coagulation indiques dans la prevention ou le traitement de pathologies thromboemboliques
PT3527563T (pt) 2013-03-12 2021-12-09 Vertex Pharma Inibidores de adn-pk
US20160016934A1 (en) 2013-03-14 2016-01-21 Respivert Limited Kinase inhibitors
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
JP6529492B2 (ja) 2013-07-11 2019-06-12 アジオス ファーマシューティカルズ， インコーポレイテッド 癌の処置のためのｉｄｈ２突然変異体阻害剤としての２，４−または４，６−ジアミノピリミジン化合物
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
EA201300843A1 (ru) * 2013-08-01 2015-04-30 Арсений Валерьевич Айбушев Карбамоилфенильные производные для остановки, предотвращения и профилактики кровотечений или усиления системы гемостаза
GB201314452D0 (en) 2013-08-13 2013-09-25 Ostara Biomedical Ltd Embryo implantation
WO2015054662A1 (en) 2013-10-10 2015-04-16 Eastern Virginia Medical School 4-((2-hydroxy-3-methoxybenzyl)amino) benzenesulfonamide derivatives as 12-lipoxygenase inhibitors
PE20161022A1 (es) 2013-10-17 2016-11-12 Vertex Pharma Cocristales de (s)-n-metil-8-(1-((2'-metil-[4,5´-bipirimidin]-6-il)amino)propan-2-il)quinolina-4-carboxamida y sus derivados deuterados como inhibidores de proteinas quinasa dependientes de adn
US9636298B2 (en) 2014-01-17 2017-05-02 Methylgene Inc. Prodrugs of compounds that enhance antifungal activity and compositions of said prodrugs
JP6630280B2 (ja) 2014-02-14 2020-01-15 レスピバート・リミテツド 抗炎症化合物としての芳香族複素環化合物
KR20240010105A (ko) 2014-03-14 2024-01-23 아지오스 파마슈티컬스 아이엔씨. 치료적으로 활성인 화합물의 약제학적 조성물
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
KR102482517B1 (ko) 2014-08-20 2022-12-28 포톨라 파마슈티컬스, 인코포레이티드 인자 xa 해독제용 동결건조된 제형
GB201501302D0 (en) 2015-01-27 2015-03-11 Ostara Biomedical Ltd Embryo implantation
MX2017016041A (es) 2015-06-11 2018-04-24 Agios Pharmaceuticals Inc Metodos para usar activadores de piruvato cinasa.
US10196383B2 (en) 2015-07-17 2019-02-05 Sunshine Lake Pharma Co., Ltd. Substituted quinazoline compounds and preparation and uses thereof
GB201514021D0 (en) 2015-08-07 2015-09-23 Arner Elias Set Jeno Novel Pyridines and their use in the treatment of cancer
GB201517523D0 (en) 2015-10-05 2015-11-18 Ostara Biomedical Ltd Methods and compositions for managing reproduction
US10653710B2 (en) 2015-10-15 2020-05-19 Agios Pharmaceuticals, Inc. Combination therapy for treating malignancies
KR20180061372A (ko) 2015-10-15 2018-06-07 아지오스 파마슈티컬스 아이엔씨. 악성 종양의 치료를 위한 조합물 요법
WO2017091757A1 (en) 2015-11-24 2017-06-01 Portola Pharmaceuticals, Inc. Isotopically enriched betrixaban
TWI739783B (zh) 2016-01-22 2021-09-21 比利時商健生藥品公司 作為nik抑制劑的新穎的經取代氰基吲哚啉衍生物
WO2017125534A1 (en) 2016-01-22 2017-07-27 Janssen Pharmaceutica Nv New 6-membered heteroaromatic substituted cyanoindoline derivatives as nik inhibitors
CN108883160B (zh) 2016-02-24 2022-06-28 博尔托拉制药公司 因子xa解毒剂的冻干制剂
RU2698202C2 (ru) * 2016-06-01 2019-08-23 Закрытое акционерное общество "ФАРМА ВАМ" СПОСОБ ПОЛУЧЕНИЯ ПРЯМОГО ИНГИБИТОРА ФАКТОРА Ха
EA037815B1 (ru) 2016-06-17 2021-05-25 Портола Фармасьютикалз, Инк. ПОЛУЧЕНИЕ ПРОИЗВОДНЫХ ФАКТОРА Xa
CA3027418A1 (en) 2016-06-30 2018-01-04 Janssen Pharmaceutica Nv Cyanoindoline derivatives as nik inhibitors
CN109641882B (zh) 2016-06-30 2022-10-28 杨森制药有限公司 作为nik抑制剂的杂芳族衍生物
TWI813078B (zh) 2016-09-02 2023-08-21 美商賽克瑞恩醫療公司 sGC刺激劑
TW201815418A (zh) 2016-09-27 2018-05-01 Vertex Pharma 使用dna破壞劑及dna-pk抑制劑之組合治療癌症的方法
WO2018069936A1 (en) 2016-10-13 2018-04-19 Mylan Laboratories Limited Polymorphs and solid dispersion of betrixaban and methods for the preparation thereof
AU2018218521C1 (en) 2017-02-07 2022-06-09 Oblique Therapeutics Ab Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer
RU2019127896A (ru) 2017-02-07 2021-03-09 Облик Терапьютикс Аб Сульфинилпиридины и их применение при лечении рака
BR112019016223A2 (pt) 2017-02-07 2020-04-07 Oblique Therapeutics Ab piridinas substituídas por heteroarilsulfonila e uso das mesmas no tratamento de câncer
BR112019016248A2 (pt) 2017-02-07 2020-04-14 Oblique Therapeutics Ab piridinas substituídas com hidrocarbilssulfonila e uso das mesmas no tratamento de câncer
WO2018229796A2 (en) 2017-06-14 2018-12-20 Mylan Laboratories Limited A process for betrixaban hydrochloride and betrixaban maleate salt
TN2020000001A1 (en) 2017-07-11 2021-10-04 Vertex Pharma Carboxamides as modulators of sodium channels
EA202090871A1 (ru) 2017-10-06 2020-07-03 Форма Терапьютикс, Инк. Ингибирование убиквитин-специфической пептидазы 30
EP3700902B8 (en) 2017-10-27 2023-08-02 Boehringer Ingelheim International GmbH Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors
WO2019207463A1 (en) 2018-04-26 2019-10-31 Pfizer Inc. 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
GB201807014D0 (en) 2018-04-30 2018-06-13 Univ Leeds Innovations Ltd Factor xlla inhibitors
IL278291B2 (en) 2018-05-17 2023-10-01 Forma Therapeutics Inc Condensed bicyclic compounds are useful as ubiquitin-specific peptidase 30 inhibitors
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
DK3860989T3 (da) 2018-10-05 2023-05-01 Forma Therapeutics Inc Kondenserede pyrroliner der fungerer som inhibitorer af ubiquitin-specifik protease 30 (usp30)
CR20210627A (es) 2019-06-18 2022-02-08 Pfizer Derivados de benzisoxazol sulfonimada
CA3164134A1 (en) 2019-12-06 2021-06-10 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels
TW202245800A (zh) 2020-02-18 2022-12-01 美商基利科學股份有限公司 抗病毒化合物
TWI777411B (zh) 2020-02-18 2022-09-11 美商基利科學股份有限公司 抗病毒化合物
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
WO2022211680A1 (ru) * 2021-03-30 2022-10-06 Общество С Ограниченной Ответственностью "Фармадиол" Способ получения антикоагулянта n-(5-хлорпиридин-2-ил)-2-({4-[этан-имидоил(метил)амино]бензоил}амино)-5-метилбензамид гидрохлорида
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
KR20230170745A (ko) 2021-04-16 2023-12-19 길리애드 사이언시즈, 인코포레이티드 아미드를 사용한 카르바뉴클레오시드를 제조하는 방법
GB202107722D0 (en) 2021-05-28 2021-07-14 Lunac Therapeutics Ltd Factor XIIA Inhibitors
TW202313593A (zh) 2021-06-04 2023-04-01 美商維泰克斯製藥公司 作為鈉通道調節劑之ｎ—（羥基烷基（雜）芳基）四氫呋喃甲醯胺
AU2022328698A1 (en) 2021-08-18 2024-02-01 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2095619A (en) * 1937-10-12 Aryl oxides
CH479557A (de) * 1961-09-11 1969-10-15 Wander Ag Dr A Verfahren zur Herstellung neuer mehrbasischer Verbindungen
GB1047245A (da) * 1963-02-15
JPS6033389B2 (ja) * 1979-02-22 1985-08-02 日産化学工業株式会社 複素環エ−テル系フェノシキ脂肪酸誘導体、その製造法および該誘導体を含有する除草剤
DE3207033C2 (de) 1981-02-27 1984-09-13 Torii & Co., Ltd., Tokyo Amidinverbindungen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Mittel
US4500714A (en) * 1981-10-15 1985-02-19 Chugai Seiyaku Kabushiki Kaisha 3-Substituted-ureido-N-pyridyl benzamides
US4588587A (en) * 1983-03-01 1986-05-13 Pennsylvania Hospital Method of treatment to inhibit metastasis
JPS59181257A (ja) 1983-03-31 1984-10-15 Chugai Pharmaceut Co Ltd ウレイドベンズアミド誘導体
JPS648675A (en) 1987-06-30 1989-01-12 Mitsubishi Electric Corp Formation of schottky gate
JP2668231B2 (ja) 1987-12-29 1997-10-27 大日精化工業株式会社 電子写真感光体
AU606808B2 (en) 1988-06-29 1991-02-14 Otsuka Pharmaceutical Factory, Inc. Arylcarboxamide substituted by alkylphosphonates, process for preparing the same and a pharmaceutical composition containing the same
JPH0418675A (ja) 1990-05-11 1992-01-22 Ricoh Co Ltd 回路図入力装置
GB9816837D0 (en) * 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
ZA928276B (en) 1991-10-31 1993-05-06 Daiichi Seiyaku Co Aromatic amidine derivates and salts thereof.
US5612360A (en) 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
EP0675899B1 (en) 1992-12-15 1999-03-17 Corvas International, Inc. NOVEL INHIBITORS OF FACTOR Xa
US5610335A (en) 1993-05-26 1997-03-11 Cornell Research Foundation Microelectromechanical lateral accelerometer
EP0798295B1 (en) 1994-12-02 2003-02-26 Yamanouchi Pharmaceutical Co. Ltd. Novel amidinonaphthyl derivative or salt thereof
CA2214685C (en) 1995-03-10 2008-05-20 Berlex Laboratories, Inc. Benzamidine derivatives their preparation and their use as anti-coagulants
EP0742208A1 (en) 1995-05-05 1996-11-13 Grelan Pharmaceutical Co., Ltd. 2-Ureido-benzamide derivatives
US5849759A (en) 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
US5994375A (en) 1996-02-12 1999-11-30 Berlex Laboratories, Inc. Benzamidine derivatives substituted by amino acid and hydroxy acid derivatives and their use as anti-coagulants
ES2189968T3 (es) * 1996-08-16 2003-07-16 Bristol Myers Squibb Pharma Co Amidinofenil-pirrolidinas,-pirrolinas,e -isoxazolidinas y derivadOS DE LOS MISMOS.
EP0934068A1 (en) 1996-09-09 1999-08-11 Smithkline Beecham Corporation Compounds and methods
WO1998028269A1 (en) 1996-12-23 1998-07-02 Du Pont Pharmaceuticals Company NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS
EP0946528B1 (en) * 1996-12-23 2003-04-09 Bristol-Myers Squibb Pharma Company OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS
EP0993448A1 (en) * 1997-06-19 2000-04-19 The Du Pont Merck Pharmaceutical Company (AMIDINO)6-MEMBERED AROMATICS AS FACTOR Xa INHIBITORS
ATE297203T1 (de) 1997-06-26 2005-06-15 Lilly Co Eli Antithrombotische mitteln
CA2294042A1 (en) 1997-06-26 1999-01-07 David Kent Herron Antithrombotic agents
JP2002510313A (ja) 1997-06-26 2002-04-02 イーライ・リリー・アンド・カンパニー 抗血栓物質
ES2248911T3 (es) 1997-06-26 2006-03-16 Eli Lilly And Company Agentes antitromboticos.
EP1001782A4 (en) 1997-08-11 2002-01-30 Boehringer Ingelheim Pharma 5,6-HETEROARYL-DIPYRIDO (2-3-b: 3 ', 2'-f) AZEPINS AND THE USE THEREOF FOR PROPHYLAXIS AND TREATMENT OF HIV INFECTIONS
CN1268116A (zh) 1997-08-27 2000-09-27 橘生药品工业株式会社 3－脒基苯胺衍生物,活化血凝固因子x抑制剂和制备这些物质的中间体
US6140351A (en) 1997-12-19 2000-10-31 Berlex Laboratories, Inc. Ortho-anthranilamide derivatives as anti-coagulants
CA2315070A1 (en) 1997-12-17 1999-07-01 Schering Aktiengesellschaft Ortho-anthranilamide derivatives as anti-coagulants
EP0937711A1 (de) 1998-02-18 1999-08-25 Roche Diagnostics GmbH Neue Thiobenzamide, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
JPH11302177A (ja) 1998-04-27 1999-11-02 Otsuka Pharmaceut Factory Inc 腎炎治療剤
PL349131A1 (en) 1998-12-09 2002-07-01 American Home Prod Acetamide and substituted acetamide-containing thiourea inhibitors of herpes viruses
BR9916086A (pt) 1998-12-09 2001-09-04 American Home Prod Composto, composição farmacêutica, método para inibir a replicação de um vìrus do herpes, método para tratar um paciente sofrendo de uma infecção por vìrus do herpes
EA200100631A1 (ru) 1998-12-09 2002-02-28 Американ Хоум Продактс Корпорейшн Ингибиторы вирусов герпеса, представляющие собой гетероциклические карбоксамидсодержащие тиомочевины, имеющие фенилендиаминогруппу
WO2000034269A1 (en) 1998-12-09 2000-06-15 American Home Products Corporation Thiourea inhibitors of herpes viruses
NZ512135A (en) 1998-12-09 2003-12-19 Wyeth Corp Alpha-methylbenzyl-containing thiourea inhibitors of herpes viruses containing a phenylenediamine group
IL143261A0 (en) 1998-12-09 2002-04-21 American Home Prod Thiourea inhibitors of herpes viruses
EP1144399A3 (en) 1998-12-09 2002-09-11 Wyeth Heterocyclic carboxamide-containing thiourea inhibitors of herpes viruses containing a substituted phenylenediamine group
ES2226485T3 (es) 1998-12-23 2005-03-16 Eli Lilly And Company Amidas aromaticas.
EP1216228B1 (en) 1999-09-17 2008-10-29 Millennium Pharmaceuticals, Inc. BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
US6720317B1 (en) * 1999-09-17 2004-04-13 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
AU2001250783A1 (en) * 2000-02-29 2001-09-12 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
AU776053B2 (en) * 2000-03-31 2004-08-26 Astellas Pharma Inc. Diazepan derivatives or salts thereof
US6373515B1 (en) * 2000-08-09 2002-04-16 Hewlett-Packard Company Variable resolution transition placement device
US7312235B2 (en) * 2001-03-30 2007-12-25 Millennium Pharmaceuticals, Inc. Benzamide inhibitors of factor Xa
CA2456173A1 (en) * 2001-07-31 2003-02-13 Wayne State University Quinoline derivatives and use thereof as antitumor agents
ES2338881T3 (es) 2003-10-09 2010-05-13 Millennium Pharmaceuticals, Inc. Benzamidas sustituidas con tioeter como inhibidores del factor xa.
AU2005257999B2 (en) 2004-06-18 2011-12-08 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
US7696352B2 (en) 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
JP5227178B2 (ja) 2005-11-08 2013-07-03 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｎ−（５−クロロ−２−ピリジニル）−２−［［４−［（ジメチルアミノ）イミノメチル］ベンゾイル］アミノ］−５−メトキシ−ベンズアミド、第Ｘａ因子阻害剤の薬学的な塩および多形体
WO2007112367A2 (en) 2006-03-27 2007-10-04 Portola Pharmaceuticals, Inc. Potassium channel modulators and platelet procoagulant activity
EP2016072B1 (en) 2006-05-05 2014-07-16 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
SG10201504425SA (en) 2006-12-08 2015-07-30 Millennium Pharm Inc Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor
CA2674924A1 (en) 2007-01-05 2008-07-17 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
EP2155195B1 (en) 2007-04-13 2014-07-16 Millennium Pharmaceuticals, Inc. Combination anticoagulant therapy with a compound that acts as a factor Xa inhibitor
US20080279845A1 (en) 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. Combination therapy with a compound acting as a platelet adp receptor inhibitor

Also Published As

Publication number Publication date
US20040097561A1 (en) 2004-05-20
US7314874B2 (en) 2008-01-01
US20180036296A1 (en) 2018-02-08
US20020002183A1 (en) 2002-01-03
DE60115394D1 (de) 2006-01-05
US20050261346A1 (en) 2005-11-24
AU2001250783A1 (en) 2001-09-12
US20130172310A1 (en) 2013-07-04
AU2001245353A1 (en) 2001-09-12
CA2401778A1 (en) 2001-09-07
US6376515B2 (en) 2002-04-23
US20070021472A1 (en) 2007-01-25
US20120083602A1 (en) 2012-04-05
US9108922B2 (en) 2015-08-18
US7727982B2 (en) 2010-06-01
US7727981B2 (en) 2010-06-01
ES2254385T3 (es) 2006-06-16
ATE311366T1 (de) 2005-12-15
US8691847B2 (en) 2014-04-08
US8063036B2 (en) 2011-11-22
US20060241153A1 (en) 2006-10-26
US20160317511A1 (en) 2016-11-03
EP1259485A2 (en) 2002-11-27
US20140377247A1 (en) 2014-12-25
HK1051539A1 (en) 2003-08-08
WO2001064642A2 (en) 2001-09-07
WO2001064643A3 (en) 2002-04-04
WO2001064643A2 (en) 2001-09-07
US6835739B2 (en) 2004-12-28
US10179124B2 (en) 2019-01-15
US20090131411A1 (en) 2009-05-21
DE60115394T2 (de) 2006-10-19
US20100298284A1 (en) 2010-11-25
US9629831B2 (en) 2017-04-25
WO2001064642A3 (en) 2002-05-02
US20030162690A1 (en) 2003-08-28
CA2401778C (en) 2010-12-21
EP1259485B1 (en) 2005-11-30
US8518977B2 (en) 2013-08-27
US7342013B2 (en) 2008-03-11

Similar Documents

Publication Publication Date Title
DK1259485T3 (da) Benzamider og beslægtede inhibitorer for faktor Xa
WO2001056989A3 (en) Inhibitors of factor xa
NZ511927A (en) Phenylglycine derivatives
WO2002026712A3 (en) Quaternary amines and related inhibitors of factor xa
BG106013A (en) New compounds and compositions as protease inhibitors
NO20021229D0 (no) Benzamider og lignende inhibitorer for faktor Xa
WO2000071507A3 (en) INHIBITORS OF FACTOR Xa
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
SE0202463D0 (sv) Novel compounds
ATE359271T1 (de) Phenylderivate
BR0014078A (pt) Inibidores de fator xa
MY133897A (en) N-(4-carb-amimidophenyl) glycineamide derivatives
WO2000071516A3 (en) INHIBITORS OF FACTOR Xa
DE60230127D1 (de) Inhibitoren von integrin alpha-v-beta-6
DE60221505D1 (de) FAKTOR Xa BENZAMIDIN INHIBITOREN
WO2001072708A3 (en) OXINDOLE INHIBITORS OF FACTOR Xa
DE60121461D1 (de) Kondensierte pyridoindolderivate
WO2001057021A3 (en) 2-[1H]-QUINOLONE AND 2-[1H]-QUINOXALONE INHIBITORS OF FACTOR Xa
WO2002026720A3 (en) PIPERAZINE BASED INHIBITORS OF FACTOR Xa
MX9709910A (es) Compuestos que contienen arginina e imitaciones de arginina, su uso y composiciones que los contienen.
SE0302756D0 (sv) Novel Compounds
ATE369348T1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
DE69803383D1 (de) Selektive inhibitoren des faktors x, eine azepinonstruktur enthaltend
WO2002026718A3 (en) Bicyclic pyrimidin-4-one based inhibitors of factor xa
WO2002026731A3 (en) Quaternary amidino based inhibitors of factor xa